Articles by Katy Marshall
There is little research on the efficacy of adding oxaliplatin to treat older patients with the disease.
Researchers specifically used data from the SEER-22 and SEER-17 registries.
The systematic review included data from 12 randomized controlled trials, 2 systematic reviews, and 1 nonrandomized study.
GNAS-mutated tumors displayed C-to-T mutation-high, aneuploidy-low molecular profile.
Cabozantinib can be used for patients with pNETs or epNETs.
Investigators calculated the C-for-benefit to evaluate evidence for HTE.
Researchers noted that CIPN was negatively connected to HRQOL across all therapy groups.
Currently, there is little research on the comparative accuracy of mpMRI versus DECT.
The study’s primary end point was overall survival in the inverse probability of treatment weighting.
The study compared neoadjuvant doublet chemotherapy, triplet chemotherapy, and doublet chemotherapy plus radiotherapy.
The AI model used predictors of recurrence and duration imatinib treatment to determine recurrence risk.
Participants received pemigatinib 13.5 mg once per day for 21-day cycles with 2 weeks on and 1 week off.
Researchers reported that a buildup of lactate was most notable in chemotherapy-resistant cancer tissues.
Median OS was 9.1 months for patients with CP-B7 and 4.7 months for those with CP-B8-C12.
The study investigated the Single Tremelimumab Regular Interval Durvalumab regimen.
Research has demonstrated that DC-based immunotherapy resulted in T-cell responses against pancreatic cancer antigens.
The potential uses of bexarotene, a retinoid, for patients with colon cancer have not been adequately explored.
While GEP-NETs are often torpid, the incidence of patients with GEP-NETs has increased over the last few years.
The study's primary end point was overall survival.
The effects of targeted therapies are deterred by a rapid emergence of resistance.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.